Locally Advanced Squamous Cell Carcinomas Of The Head And Neck Excluding Lip In Combination With Concurrent Chemoradiation — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for locally advanced squamous cell carcinomas of the head and neck excluding lip in combination with concurrent chemoradiation. 1 active patents protecting 1 drugs from 0+ originators. First major cliff: 2041. Daily refresh.

1
Approved drugs
1
Active US patents
55/100
Avg vulnerability
—
Annual revenue covered

Originators in Locally Advanced Squamous Cell Carcinomas Of The Head And Neck Excluding Lip In Combination With Concurrent Chemoradiation

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating locally advanced squamous cell carcinomas of the head and neck excluding lip in combination with concurrent chemoradiation. Each bar = one year. Y-axis scaled to peak year (1 patents).

No expiries in next 15 years.

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
HYDROXYUREA — 1 55 — 2041-12-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12409156 HYDROXYUREA formulation 55 2041-12-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12409156 HYDROXYUREA formulation 55 2041-12-23

Related